A novel electrochemical strategy for NT-proBNP detection using IMFET for monitoring heart failure by saliva analysis.


Journal

Talanta
ISSN: 1873-3573
Titre abrégé: Talanta
Pays: Netherlands
ID NLM: 2984816R

Informations de publication

Date de publication:
01 Jan 2023
Historique:
received: 07 06 2022
revised: 15 07 2022
accepted: 19 07 2022
pubmed: 12 8 2022
medline: 20 10 2022
entrez: 11 8 2022
Statut: ppublish

Résumé

Heart failure (HF) is a chronic cardiovascular disease that represents main cause of mortality worldwide, particularly for elderly. N-terminal pro-brain natriuretic peptide (NT-proBNP) was identified as the gold standard biomarker for HF diagnosis and therapy monitoring. Presently, saliva analysis represents an emerging and powerful tool for clinical applications and electrochemical immunosensors have shown their potential in Healthcare applications as selective and reliable systems for detecting clinical biomarkers. This work presents the detection of NT-proBNP in saliva samples by an immunologically modified Field effect Transistor (IMFET). TESUD ((11-triethoxysilyl) undecanal) was used as cross-linker to immobilise anti-NT-proBNP antibody onto the device. Our IMFET that was then tested in different matrices (e.g. phosphate buffered saline (PBS), artificial saliva and human saliva) using electrochemical impedance spectroscopy (EIS), and it resulted selective to NT-proBNP with good sensitivity (detection limit of 0.02 pg/mL) and a wide linear range (0.02-1 pg/mL and 0.5-20 pg/mL). Finally, NT-proBNP concentration in ten saliva samples was determined by performing the standard addition method. An enzyme-linked immunosorbent assay was used for confirming IMFET results, highlighting both IMFET accuracy (analyte recovery of 99 ± 8%) and precision (coefficient of variation always <10%), and supporting the suitability of the device for determining salivary NT-proBNP.

Identifiants

pubmed: 35952499
pii: S0039-9140(22)00555-0
doi: 10.1016/j.talanta.2022.123759
pii:
doi:

Substances chimiques

Biomarkers 0
Natriuretic Peptide, Brain 114471-18-0
Peptide Fragments 0
Phosphates 0
pro-brain natriuretic peptide (1-76) 0
Saliva, Artificial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123759

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hamdi Ben Halima (H)

Institute of Analytical Sciences (ISA) - UMR 5280, Claude Bernard Lyon 1 University (UCBL), 69100, Lyon, France.

Francesca G Bellagambi (FG)

Institute of Analytical Sciences (ISA) - UMR 5280, Claude Bernard Lyon 1 University (UCBL), 69100, Lyon, France. Electronic address: francesca.bellagambi@dcci.unipi.it.

Marie Hangouët (M)

Institute of Analytical Sciences (ISA) - UMR 5280, French National Center for Scientific Research (CNRS), 69100, Lyon, France.

Albert Alcacer (A)

Institute of Microelectronics of Barcelona (IMB-CNM, CSIC), Campus UAB, 08193 Bellaterra, Barcelona, Spain.

Norman Pfeiffer (N)

Fraunhofer IIS, Fraunhofer Institute for Integrated Circuits, 91058 Erlangen, Germany.

Albert Heuberger (A)

Information Technology (LIKE), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91058 Erlangen, Germany.

Nadia Zine (N)

Institute of Analytical Sciences (ISA) - UMR 5280, Claude Bernard Lyon 1 University (UCBL), 69100, Lyon, France.

Joan Bausells (J)

Institute of Microelectronics of Barcelona (IMB-CNM, CSIC), Campus UAB, 08193 Bellaterra, Barcelona, Spain.

Abdelhamid Elaissari (A)

Institute of Analytical Sciences (ISA) - UMR 5280, Claude Bernard Lyon 1 University (UCBL), 69100, Lyon, France.

Abdelhamid Errachid (A)

Institute of Analytical Sciences (ISA) - UMR 5280, Claude Bernard Lyon 1 University (UCBL), 69100, Lyon, France. Electronic address: abdelhamid.errachid-el-salhi@univ-lyon1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH